Consensus document: management of heart failure in type 2 diabetes mellitus.

Cardiovascular System Consensus Diabetes Mellitus, Type 2 / complications Heart Failure / epidemiology Humans Hypoglycemic Agents / therapeutic use
Diagnosis Drug Heart failure Trials Type 2 diabetes mellitus

Journal

Heart failure reviews
ISSN: 1573-7322
Titre abrégé: Heart Fail Rev
Pays: United States
ID NLM: 9612481

Informations de publication

Date de publication:
09 2021
Historique:
pubmed: 25 5 2020
medline: 15 12 2021
entrez: 25 5 2020
Statut: ppublish

Résumé

Type 2 diabetes mellitus (T2DM) is a known predisposing factor for heart failure (HF). The growing burden of these two conditions and their impact on health of the individual and on society in general needs urgent attention from the health care professionals. Availability of multiple treatment choices for managing T2DM and HF may make therapeutic decisions more complex for clinicians. Recent cardiovascular outcome trials of antidiabetic drugs have added very robust evidence to effectively manage subjects with this dual condition. This consensus statement provides the prevalence trends and the impact of this dual burden on patients. In addition, it concisely narrates the types of HF, the different treatment algorithms, and recommendations for physicians to comprehensively manage such patients.

Identifiants

DOI: 10.1007/s10741-020-09955-7 PMID: 32447488
pubmed: 32447488
doi: 10.1007/s10741-020-09955-7
pii: 10.1007/s10741-020-09955-7
doi:

Substances chimiques

Hypoglycemic Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1037-1062

Informations de copyright

© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Références

Kannel W, McGee D (1979) Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 59:8–13
pubmed: 758126 doi: 10.1161/01.CIR.59.1.8
Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018) The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions. Heart Fail Rev 23:303–323
pubmed: 29516230 pmcid: 5937871 doi: 10.1007/s10741-018-9685-0
Ingle L, Reddy P, Clark AL, Cleland JG (2006) Diabetes lowers six-minute walk test performance in heart failure. J Am Coll Cardiol 47:1909–1910
pubmed: 16682322 doi: 10.1016/j.jacc.2006.02.005
Egstrup M, Kistorp CN, Schou M, Høfsten DE, Møller JE, Tuxen CD, Gustafsson I (2013) Abnormal glucose metabolism is associated with reduced left ventricular contractile reserve and exercise intolerance in patients with chronic heart failure. Eur Heart J Cardiovasc Imaging 14:349–357
pubmed: 22898711 doi: 10.1093/ehjci/jes165
Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, Køber L, McKelvie R, Zile MR, Anand IS, Komajda M, Gottdiener JS, Carson PE, McMurray J (2017) Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-Preserve trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 135:724–735
pubmed: 28052977 doi: 10.1161/CIRCULATIONAHA.116.024593
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, de Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fèvre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gosselin R, Grainger R, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons R, Ma J, Mabweijano J, MacIntyre M, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty J, McDermott M, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, O’Donnell M, O’Hanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA 3rd, Popova S, Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, de Leòn FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf M, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD, Murray CJ, AlMazroa M, Memish ZA (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 380:2163–2196
Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CSP, Sato N, Shah AN, Gheorghiade M (2014) The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63:1123–1133
pubmed: 24491689 doi: 10.1016/j.jacc.2013.11.053 pmcid: 24491689
Huffman MD, Prabhakaran D (2010) Heart failure: epidemiology and prevention in India. Natl Med J India 23:283–288
pubmed: 21250584 pmcid: 3913650
Institute of Health Metrics and Evaluation (2017) GBD compare. https://vizhub.healthdata.org/gbd-compare/ [Accessed 6
Chaturvedi V, Parakh N, Seth S, Gupta N, Misra P, Rai SK, Anand K et al (2016) Heart failure in India: the INDUS (INDiaUkieri Study) study. J Pract Cardiovasc Sci 2:28–35
doi: 10.4103/2395-5414.182988
Dokainish H, Teo K, Zhu J et al (2017) INTER-CHF Investigators. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. Lancet Glob Health 5:e665–e672
pubmed: 28476564 doi: 10.1016/S2214-109X(17)30196-1
Harikrishnan S, Sanjay G, Anees T et al (2015) Trivandrum Heart Failure Registry. Clinical presentation, management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: the Trivandrum Heart Failure Registry. Eur J Heart Fail 17:794–800
pubmed: 26011246 doi: 10.1002/ejhf.283
Harikrishnan S, Sanjay G, Agarwal A, Kumar NP, Kumar KK, Bahuleyan CG, Vijayaraghavan G, Viswanathan S, Sreedharan M, Biju R, Rajalekshmi N, Nair T, Suresh K, Jeemon P (2017) One-year mortality outcomes and hospital readmissions of patients admitted with acute heart failure: data from the Trivandrum Heart Failure Registry in Kerala, India. Am Heart J 189:193–199
pubmed: 28625377 doi: 10.1016/j.ahj.2017.03.019
Lesyuk W, Kriza C, Kolominsky-Rabas P (2018) Cost-of-illness studies in heart failure: a systematic review 2004-2016. BMC Cardiovasc Disord 18:74
pubmed: 29716540 pmcid: 5930493 doi: 10.1186/s12872-018-0815-3
Cook C, Cole G, Asaria P, Jabbour R, Francis DP (2014) The annual global economic burden of heart failure. Int J Cardiol 171:368–376
pubmed: 24398230 doi: 10.1016/j.ijcard.2013.12.028
Einarson TR, Acs A, Ludwig C, Panton UH (2018) Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol 17:83
pubmed: 29884191 pmcid: 5994068 doi: 10.1186/s12933-018-0728-6
Lawson CA, Solis-Trapala I, Dahlstrom U et al (2018) Comorbidity health pathways in heart failure patients: a sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry. PLoS Med 15:e1002540a
doi: 10.1371/journal.pmed.1002540
Carrasco-Sánchez FJ, Gomez-Huelgas R, Formiga F et al (2014) RICA investigators. Association between type-2 diabetes mellitus and post-discharge outcomes in heart failure patients: findings from the RICA registry. Diabetes Res Clin Pract 104:410–419
pubmed: 24768593 doi: 10.1016/j.diabres.2014.03.015
Tromp J, Tay WT, Ouwerkerk W et al (2018) ASIAN-HF authors. Multimorbidity in patients with heart failure from 11 Asian regions: a prospective cohort study using the ASIAN-HF registry. PLoS Med 15:e1002541
pubmed: 29584721 pmcid: 5870945 doi: 10.1371/journal.pmed.1002541
Mishra S, Mohan JC, Nair T, Chopra VK, Harikrishnan S, Guha S, Ramakrishnan S, Ray S, Sethi R, Samal UC, Sarat Chandra K, Hiremath MS, Banerjee AK, Kumar S, Das MK, Deb PK, Bahl VK (2018) Management protocols for chronic heart failure in India. Indian Heart J 70:105–127
pubmed: 29455764 doi: 10.1016/j.ihj.2017.11.015
Chopra VK, Mittal S, Bansal M, Singh B, Trehan N (2019) Clinical profile and one-year survival of patients with heart failure with reduced ejection fraction: the largest report from India. Indian Heart J. https://doi.org/10.1016/j.ihj.2019.07.008
Wang Y, Negishi T, Negishi K, Marwick TH (2015) Prediction of heart failure in patients with type 2 diabetes mellitus-a systematic review and meta-analysis. Diabetes Res Clin Pract 108:55–66
pubmed: 25686509 doi: 10.1016/j.diabres.2015.01.011
Parry HM, Deshmukh H, Levin D, van Zuydam N, Elder DH, Morris AD, Struthers AD, Palmer CN, Doney AS, Lang CC (2015) Both high and low HbA1c predict incident heart failure in type 2 diabetes mellitus. Circ Heart Fail 8:236–242
pubmed: 25561089 pmcid: 4366571 doi: 10.1161/CIRCHEARTFAILURE.113.000920
Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S (2016) Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol 12:610–623
pubmed: 27573728 doi: 10.1038/nrneph.2016.113
Lawson CA, Testani JM, Mamas M, Damman K, Jones PW, Teece L, Kadam UT (2018) Chronic kidney disease, worsening renal function and outcomes in a heart failure community setting: a UK national study. Int J Cardiol 267:120–127.b
pubmed: 29957251 pmcid: 6024224 doi: 10.1016/j.ijcard.2018.04.090
Kristensen SL, Preiss D, Jhund PS et al (2016) PARADIGM-HF Investigators and Committees.. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 9:e002560.a
doi: 10.1161/CIRCHEARTFAILURE.115.002560
Anjana RM, Pradeepa R, Deepa M et al (2011) ICMR–INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia 54:3022–3027
pubmed: 21959957 doi: 10.1007/s00125-011-2291-5
Patel S, Nanda R, Abraham J, Sahoo S, Ganguly A, Mohapatra E (2017) Prediabetes and undiagnosed diabetes mellitus: the hidden danger. Indian J Med Biochem 21:91–95
doi: 10.5005/jp-journals-10054-0028
Serhiyenko VA, Serhiyenko AA (2018) Cardiac autonomic neuropathy: risk factors, diagnosis and treatment. World J Diabetes 9:1–24
pubmed: 29359025 pmcid: 5763036 doi: 10.4239/wjd.v9.i1.1
Nyström T, Santos-Pardo I, Hedberg F et al (2017) Effects on subclinical heart failure in type 2 diabetic subjects on liraglutide treatment vs. glimepiride both in combination with metformin: a randomized open parallel-group study. Front Endocrinol (Lausanne) 8:325
doi: 10.3389/fendo.2017.00325
König P, Mayer O, Bruthans J et al (2019) The prognostic importance of subclinical heart failure in stable coronary heart disease patients. Acta Cardiol 3:1–8
Rajput R, Jagdish SSB, Rattan A (2002) Echocardiographic and Doppler assessment of cardiac functions in patients of non-insulin dependent diabetes mellitus. JIACM 3:164–168
Faden G, Faganello G, De Feo S et al (2013) The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes Res Clin Pract 101:309–316
pubmed: 23886659 doi: 10.1016/j.diabres.2013.07.004 pmcid: 23886659
Schocken DD, Benjamin EJ, Fonarow GC et al (2008) American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; Functional Genomics and Translational Biology Interdisciplinary Working Group. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 117:2544–2565
pubmed: 18391114 doi: 10.1161/CIRCULATIONAHA.107.188965 pmcid: 18391114
Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, Pinkett T, Ghali JK, Wilson AC (1996) Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 77:1017–1020
pubmed: 8644628 doi: 10.1016/S0002-9149(97)89163-1 pmcid: 8644628
Wang TJ (2003) Natural history of asymptomatic left ventricular systolic dysfunction in the 3746 community. Circulation. 108:977–982
pubmed: 12912813 doi: 10.1161/01.CIR.0000085166.44904.79 pmcid: 12912813
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW (2009) 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 119:e391–e479
pubmed: 19324966 pmcid: 19324966
Yancy CW, Jessup M, Bozkurt B, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:e147–e239
pubmed: 23747642 doi: 10.1016/j.jacc.2013.05.019 pmcid: 23747642
Ponikowski P, Voors AA, Anker SD et al (2016) Authors/Task Force Members; Document Reviewers.. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891–975
pubmed: 27207191 doi: 10.1002/ejhf.592 pmcid: 27207191
Johansson I, Dahlström U, Edner M, Näsman P, Rydén L, Norhammar A (2018) Type 2 diabetes and heart failure: characteristics and prognosis in preserved, mid-range and reduced ventricular function. Diab Vasc Dis Res 15:494–503
pubmed: 30176743 doi: 10.1177/1479164118794619 pmcid: 30176743
MacDonald MR, Petrie MC, Varyani F et al (2008) CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29:1377–1385
pubmed: 18413309 doi: 10.1093/eurheartj/ehn153
Levelt E, Mahmod M, Piechnik SK, Ariga R, Francis JM, Rodgers CT, Clarke WT, Sabharwal N, Schneider JE, Karamitsos TD, Clarke K, Rider OJ, Neubauer S (2016) Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes. Diabetes. 65:44–52
pubmed: 26438611 pmcid: 26438611
Basta G, Schmidt AM, De Caterina R (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63:582–592
pubmed: 15306213 doi: 10.1016/j.cardiores.2004.05.001 pmcid: 15306213
Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595–602
pubmed: 4263660 doi: 10.1016/0002-9149(72)90595-4 pmcid: 4263660
Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, Goodman SG, Goldenberg RM, al-Omran M, Gilbert RE, Bhatt DL, Leiter LA, Jüni P, Zinman B, Connelly KA (2019) Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 140(21):1693–1702
pubmed: 31434508 doi: 10.1161/CIRCULATIONAHA.119.042375 pmcid: 31434508
Brown AJM, Lang C, McCrimmon R, Struthers A et al (2019) A randomised controlled trial of dapagliflozin on left ventricular hypertrophy in patients with type two diabetes. The DAPA-LVH Trial. Circulation 140:A10643
Schilling JD (2015) The mitochondria in diabetic heart failure: from pathogenesis to therapeutic promise. Antioxid Redox Signal 22:1515–1526
pubmed: 25761843 pmcid: 4449623 doi: 10.1089/ars.2015.6294
Kayama Y, Raaz U, Jagger A, Adam M, Schellinger IN, Sakamoto M, Suzuki H, Toyama K, Spin JM, Tsao PS (2015) Diabetic cardiovascular disease induced by oxidative stress. Int J Mol Sci 16:25234–25263
pubmed: 26512646 pmcid: 4632800 doi: 10.3390/ijms161025234
Verma SK, Garikipati VNS, Kishore R (1863) Mitochondrial dysfunction and its impact on diabetic heart. Biochim Biophys Acta Mol basis Dis 2017:1098–1105
Chong CR, Clarke K, Levelt E (2017) Metabolic remodelling in diabetic cardiomyopathy. Cardiovasc Res 113:422–430
pubmed: 28177068 pmcid: 5412022 doi: 10.1093/cvr/cvx018
Orsborne C, Chaggar PS, Shaw SM, Williams SG (2017) The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future. Postgrad Med J 93:29–37
pubmed: 27671772 doi: 10.1136/postgradmedj-2016-134045
Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, Paulus WJ, Rossignol P, Taegtmeyer H, Bauersachs J, Bayes-Genis A, Brutsaert D, Bugger H, Clarke K, Cosentino F, de Keulenaer G, Dei Cas A, González A, Huelsmann M, Iaccarino G, Lunde IG, Lyon AR, Pollesello P, Rena G, Riksen NP, Rosano G, Staels B, van Laake L, Wanner C, Farmakis D, Filippatos G, Ruschitzka F, Seferovic P, de Boer RA, Heymans S (2018) Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Heart J 39:4243–4254
pubmed: 30295797 pmcid: 6302261 doi: 10.1093/eurheartj/ehy596
Yancy CW, Jessup M, Bozkurt B et al (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 136:e137–e161
pubmed: 28455343 doi: 10.1161/CIR.0000000000000509
Chow SL, Maisel AS, Anand I, American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; and Council on Quality of Care and Outcomes Research et al (2017) Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation 135:e1054–e1091
pubmed: 28446515 doi: 10.1161/CIR.0000000000000490
Nadar SK, Shaikh MM (2019) Biomarkers in routine heart failure clinical care. Card Fail Rev 5:50–56
pubmed: 30847246 pmcid: 6396063 doi: 10.15420/cfr.2018.27.2
Maisel AS, Krishnaswamy P, Nowak RM et al (2002) Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161–167
doi: 10.1056/NEJMoa020233
Januzzi JL Jr, Camargo CA, Anwaruddin S et al (2005) The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95:948–954
pubmed: 15820160 doi: 10.1016/j.amjcard.2004.12.032 pmcid: 15820160
Omar HR, Guglin M (2016) Discharge BNP is a stronger predictor of 6-month mortality in acute heart failure compared with baseline BNP and admission-to-discharge percentage BNP reduction. Int J Cardiol 221:1116–1122
pubmed: 27467969 doi: 10.1016/j.ijcard.2016.07.117 pmcid: 27467969
Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J, Maisel AS, Fitzgerald RL (2008) Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 14:732–738
pubmed: 18995177 doi: 10.1016/j.cardfail.2008.06.415 pmcid: 18995177
Bayes-Genis A, Pascual-Figal D, Januzzi JL, Maisel A, Casas T, Valdés Chávarri M, Ordóñez-Llanos J (2010) Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Rev Esp Cardiol 63:1171–1178
pubmed: 20875357 doi: 10.1016/S0300-8932(10)70249-9
Gehlken C, Suthahar N, Meijers WC, de Boer RA (2018) Galectin-3 in heart failure: an update of the last 3 years. Heart Fail Clin 14:75–92
pubmed: 29153203 doi: 10.1016/j.hfc.2017.08.009
Stelzle D, Shah ASV, Anand A, Strachan FE, Chapman AR, Denvir MA, Mills NL, McAllister D (2018) High-sensitivity cardiac troponin I and risk of heart failure in patients with suspected acute coronary syndrome: a cohort study. Eur Heart J Qual Care Clin Outcomes 4:36–42
pubmed: 29045610 doi: 10.1093/ehjqcco/qcx022
Mishra S et al (2018) Indian Heart J 70:105–127
pubmed: 29455764 doi: 10.1016/j.ihj.2017.11.015
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T et al (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29(4):277–314
pubmed: 27037982 pmcid: 27037982 doi: 10.1016/j.echo.2016.01.011
Bajaj S (2018) RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. Int J Diabetes Dev Ctries 38(Suppl 1):1–115
pubmed: 29527102 doi: 10.1007/s13410-018-0604-7
ADA (2020) Standards of medical care in diabetes—2020. Available from: https://care.diabetesjournals.org/content/diacare/suppl/2019/12/20/43.Supplement_1.DC1/DC_43_S1_2020.pdf . Accessed 20 Feb 2020
AACE/ACE (2020) Consensus statement by The American Association Of Clinical Endocrinologists And American College Of Endocrinology on the comprehensive type 2 diabetes management algorithm–2020 executive summary. Available from: https://www.aace.com/pdfs/diabetes/algorithm-exec-summary.pdf . Accessed 20 Feb 2020
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet 352:837–853
doi: 10.1016/S0140-6736(98)07019-6
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M et al (2008) ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572
pubmed: 18539916 doi: 10.1056/NEJMicm066227
The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559
pmcid: 4551392 doi: 10.1056/NEJMoa0802743 pubmed: 4551392
Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, for the VADT Investigators et al; Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes [published correction appears in N Engl J Med. 2015;373:198]. N Engl J Med 2015;372:2197–2206
Skrtic S, Cabrera C, Olsson M, Schnecke V, Lind M (2017) Contemporary risk estimates of three HbA1c variables in relation to heart failure following diagnosis of type 2 diabetes. Heart. 103:353–358
pubmed: 27647169 doi: 10.1136/heartjnl-2016-309806
Lind M, Olsson M, Rosengren A, Svensson AM, Bounias I, Gudbjornsdottir S (2012) The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia. 55:2946–2953
pubmed: 22895807 doi: 10.1007/s00125-012-2681-3
Blecker S, Park H, Katz SD (2016) Association of HbA1c with hospitalization and mortality among patients with heart failure and diabetes. BMC Cardiovasc Disord 16:99
pubmed: 27206478 pmcid: 4875651 doi: 10.1186/s12872-016-0275-6
Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ et al (2019) Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322(12):1155–1166
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322a
pubmed: 4985288 pmcid: 4985288 doi: 10.1056/NEJMoa1603827
Marso SP, Bain SC, Consoli A et al (2016) SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844b
pubmed: 27633186 doi: 10.1056/NEJMoa1607141
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, ELIXA Investigators et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373(23):2247–2257
pubmed: 26630143 doi: 10.1056/NEJMoa1509225
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, EXSCEL Study Group (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377(13):1228–1239
pubmed: 28910237 doi: 10.1056/NEJMoa1612917
Bethel MA, Patel RA, Merrill P, EXSCEL Study Group et al (2018) Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 6:105–113
pubmed: 29221659 doi: 10.1016/S2213-8587(17)30412-6
Hernandez AF, Green JB, Janmohamed S, Harmony Outcomes committees and investigators et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392:1519–1529
pubmed: 30291013 doi: 10.1016/S0140-6736(18)32261-X
Gerstein HC, Colhoun HM, Dagenais GR, REWIND Investigators et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121–130
pubmed: 31189511 doi: 10.1016/S0140-6736(19)31149-3
Green JB, Bethel MA, Armstrong PW, TECOS Study Group et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242
pubmed: 26052984 doi: 10.1056/NEJMoa1501352
Scirica BM, Braunwald E, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators* et al (2014) Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130:1579–1588
pubmed: 25189213 doi: 10.1161/CIRCULATIONAHA.114.010389
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL et al (2013) EXAMINE: alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335
pubmed: 23992602 doi: 10.1056/NEJMoa1305889
McMurray JJV, Ponikowski P, Bolli GB, VIVIDD Trial Committees and Investigators et al (2018) Effects of vildagliptin on ventricular function in patients with type 2 diabetes and heart failure: a randomized placebo-controlled trial. JACC Heart Fail 6:8–17
pubmed: 29032139 doi: 10.1016/j.jchf.2017.08.004
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire D, Wilding JPH, Sabatine MS (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 393:31–39
pubmed: 30424892 doi: 10.1016/S0140-6736(18)32590-X
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
pubmed: 26378978 pmcid: 26378978 doi: 10.1056/NEJMoa1504720
Wiviott SD, Raz I, Bonaca MP, DECLARE–TIMI 58 Investigators et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357
pubmed: 30415602 pmcid: 30415602 doi: 10.1056/NEJMoa1812389
Mahaffey KW, Neal B, Perkovic V et al (2018) CANVAS Program Collaborative Group. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 137:323–334
pubmed: 29133604 pmcid: 5777572 doi: 10.1161/CIRCULATIONAHA.117.032038
Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire D, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD (2019) Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 139:2528–2536
pubmed: 30882238 doi: 10.1161/CIRCULATIONAHA.119.040130
Singh AK, Unnikrishnan AG, Zargar AH, Kumar A, Das AK, Saboo B, Sinha B, Gangopadhyay KK, Talwalkar PG, Ghosal S, Kalra S, Joshi S, Sharma SK, Sriram U, Mohan V (2019) Evidence based consensus on positioning of SGLT2i in type 2 diabetes mellitus in Indians. Diabetes Ther 10:393–428
pubmed: 30706366 pmcid: 6437257 doi: 10.1007/s13300-019-0562-1
Solini A, Giannini L, Seghieri M et al (2017) Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol 16:138
pubmed: 29061124 pmcid: 5654086 doi: 10.1186/s12933-017-0621-8
Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ (2016) SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia. 59:1333–1339
pubmed: 27112340 pmcid: 4901113 doi: 10.1007/s00125-016-3956-x
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets D, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM, DAPA-HF Trial Committees and Investigators (2019) DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995–2008
pubmed: 31535829 doi: 10.1056/NEJMoa1911303
Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, et al Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41(9):1529–1538
Granger CB, McMurray JJ, Yusuf S, CHARM Investigators and Committees et al (2003) Effect of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM Alternative trial. Lancet 362:772–776
pubmed: 13678870 doi: 10.1016/S0140-6736(03)14284-5
Tai C, Gan T, Zou L, Sun Y, Zhang Y, Chen W (2017) Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 17:257
pubmed: 28982370 pmcid: 5629775 doi: 10.1186/s12872-017-0686-z
Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, PARADIGM-HF Investigators and Committees et al (2016) Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 9(1):e002560
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709–717
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21
pubmed: 21073363 doi: 10.1056/NEJMoa1009492
Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41(9):1529–1538
pubmed: 12742294 doi: 10.1016/S0735-1097(03)00262-6
Tsujimoto T, Sugiyama T, Shapiro MF, Noda M, Kajio H (2017) Risk of cardiovascular events in patients with diabetes mellitus on β-blockers. Hypertension. 70:103–110
pubmed: 28559400 doi: 10.1161/HYPERTENSIONAHA.117.09259
Komajda M, Tavazzi L, Francq BG, SHIFT Investigators et al (2015) Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail 17:1294–1301
pubmed: 26377342 doi: 10.1002/ejhf.347
Investigators SOLVD, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325(5):293–302
doi: 10.1056/NEJM199108013250501
(1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 353(9146):9–13
MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001–2007
Eichhorn EJ, Bristow MR (2001) The carvedilol prospective randomized cumulative survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med 2:20–23
pubmed: 11806769 pmcid: 59648 doi: 10.1186/CVM-2-1-020
Dunlay SM, Roger VL, Redfield MM (2017) Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 14:591–602
pubmed: 28492288 doi: 10.1038/nrcardio.2017.65
Smaha LA, American Heart Association (2004) The American Heart Association get with the guidelines program. Am Heart J 148(Suppl):S46–S48
pubmed: 15514634 doi: 10.1016/j.ahj.2004.09.015
McHugh K, DeVore AD, Wu J, Matsouaka RA, Fonarow GC, Heidenreich PA, Yancy CW, Green JB, Altman N, Hernandez AF (2019) J Am Coll Cardiol 73(5):602–611
pubmed: 30732715 doi: 10.1016/j.jacc.2018.11.033
Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S, Granger CB, Pfeffer MA, McMurray J, Solomon SD (2018) Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 20:1230–1239
pubmed: 29431256 doi: 10.1002/ejhf.1149
Aguilar D, Deswal A, Ramasubbu K, Mann DL, Bozkurt B (2010) Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol 105:373–377
pubmed: 20102951 doi: 10.1016/j.amjcard.2009.09.041
Zheng SL, Chan FT, Nabeebaccus AA, Shah AM, McDonagh T, Okonko DO, Ayis S (2018) Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart. 104(5):407–415
pubmed: 28780577 doi: 10.1136/heartjnl-2017-311652
Solomon SD, JV, Anand IS et al (2019) Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609–1620
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J (2003) CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362:777–781
pubmed: 13678871 doi: 10.1016/S0140-6736(03)14285-7
Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456–2467
pubmed: 19001508 doi: 10.1056/NEJMoa0805450
Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, PEP-CHF Investigators (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27:2338–2345
pubmed: 16963472 doi: 10.1093/eurheartj/ehl250
Edelmann F, Wachter R, Schmidt AG et al (2013) Aldo-DHF Investigators Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309:781–791
pubmed: 23443441 doi: 10.1001/jama.2013.905
Flather MD, Shibata MC, Coats AJ et al (2005) SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215–225
pubmed: 15642700 doi: 10.1093/eurheartj/ehi115
Yamamoto K, Origasa H, Hori M, J-DHF Investigators (2013) Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 15:110–118
pubmed: 22983988 doi: 10.1093/eurjhf/hfs141
Liu LC, Hummel YM, van der Meer P, Hoendermis ES et al (2017) Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. Eur J Heart Fail 19:116–125
pubmed: 27873388 doi: 10.1002/ejhf.662
Bardy GH, Lee KL, Mark DB et al (2005) Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med 352:225–237
pubmed: 15659722 doi: 10.1056/NEJMoa043399
Moss AJ, Zareba W, Hall WJ et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877–883
pubmed: 11907286 doi: 10.1056/NEJMoa013474
Ghali JK, Boehmer J, Feldman AM, Saxon LA, Demarco T, Carson P, Yong P, Galle EG, Leigh J, Ecklund FL, Bristow MR (2007 Nov) Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. J Card Fail 13(9):769–773
pubmed: 17996827 doi: 10.1016/j.cardfail.2007.06.723
Wittenberg SM, Cook JR, Hall WJ, McNitt S, Zareba W, Moss AJ (2005) Multicenter Automatic Defibrillator Implantation Trial. Comparison of efficacy of implanted cardioverter-defibrillator in patients with versus without diabetes mellitus. Am J Cardiol 96(3):417–419
pubmed: 16054472 doi: 10.1016/j.amjcard.2005.03.090
Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 297:1319–1331
pubmed: 17384437 doi: 10.1001/jama.297.12.1319
Matsuzaki M, Hori M, Izumu T, Fukunami M (2011) Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 25(Suppl 1):S33–S45
pubmed: 22120092 doi: 10.1007/s10557-011-6304-x
Choi HM, Park MS, Youn JC (2019) Update on heart failure management and future directions. Korean J Intern Med 34:11–43
pubmed: 30612416 doi: 10.3904/kjim.2018.428
Gustafsson F, Guarracino F, Schwinger RHG (2017) The inodilator levosimendan as a treatment for acute heart failure in various settings. Eur Heart J Suppl 19(Suppl C):C2–C7
pubmed: 29249904 pmcid: 5932561 doi: 10.1093/eurheartj/sux001
Hutchings DC, Anderson SG, Caldwell JL, Trafford AW (2018) Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart. 104:1244–1250
pubmed: 29519873 doi: 10.1136/heartjnl-2017-312865
Levine AR, Helbling NL, Chien N, Bachman TN, Simon MA, Gladwin MT (2018) Abstract 17077: acute hemodynamic effects of oral nitrite in pulmonary hypertension related to heart failure with preserved ejection fraction (PH-HFpEF). Circulation 138:A17077
doi: 10.1161/circ.138.suppl_1.17077
Teerlink JR, Felker GM, McMurray JJV, COSMIC-HF Investigators et al (2016) Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 388:2895–2903
pubmed: 27914656 doi: 10.1016/S0140-6736(16)32049-9
Machaj F, Dembowska E, Rosik J, Szostak B, Mazurek-Mochol M, Pawlik A (2019) New therapies for the treatment of heart failure: a summary of recent accomplishments. Ther Clin Risk Manag 15:147–155
pubmed: 30774351 pmcid: 6348963 doi: 10.2147/TCRM.S179302
Maurer MS, Schwartz JH, Gundapaneni B et al (2018) ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007–1016
pubmed: 30145929 doi: 10.1056/NEJMoa1805689
Ridker PM, Everett BM, Thuren T, MacFadyen J, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, CANTOS Trial Group (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131
pubmed: 28845751 doi: 10.1056/NEJMoa1707914 pmcid: 28845751
Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ, Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators (2011) Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID) a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 124:304–313
pubmed: 21709064 pmcid: 5843948 doi: 10.1161/CIRCULATIONAHA.111.022889
Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, Hajjar RJ (2014) Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res 114:101–108
pubmed: 24065463 doi: 10.1161/CIRCRESAHA.113.302421
Tompkins BA, Rieger AC, Florea V et al (2018) Comparison of mesenchymal stem cell efficacy in ischemic versus nonischemic dilated cardiomyopathy. J Am Heart Assoc 7:e008460
pubmed: 30005555 pmcid: 6064862 doi: 10.1161/JAHA.117.008460
Park M, Yoon YS (2018) Cardiac regeneration with human pluripotent stem cell-derived cardiomyocytes. Korean Circ J 48:974–988
pubmed: 30334384 pmcid: 6196153 doi: 10.4070/kcj.2018.0312
Available at https://clinicaltrials.gov/ct2/show/NCT03057977 [Accessed on 5
Available at https://clinicaltrials.gov/ct2/show/NCT03448419 [Accessed on 5
Available at https://clinicaltrials.gov/ct2/show/NCT03877237 [Accessed on 5
Available at https://clinicaltrials.gov/ct2/show/NCT03066804 [Accessed on 5
Available at https://clinicaltrials.gov/ct2/show/NCT02884206 [Accessed on 5
Available at https://clinicaltrials.gov/ct2/show/NCT03037580 [Accessed on 5
Available at https://clinicaltrials.gov/ct2/show/NCT01599117 [Accessed on 5
Available at https://clinicaltrials.gov/ct2/show/NCT02713126 [Accessed on 5
Available at https://clinicaltrials.gov/ct2/show/NCT03057951 [Accessed on 5
Available at https://clinicaltrials.gov/ct2/show/NCT03448406 [Accessed on 5
Available at https://clinicaltrials.gov/ct2/show/NCT03030235 [Accessed on 5
Available at https://clinicaltrials.gov/ct2/show/NCT03877224 [Accessed on 5
Available at https://clinicaltrials.gov/ct2/show/NCT03619213 [Accessed on 5
Available at https://clinicaltrials.gov/ct2/show/NCT03416270 [Accessed on 5

Auteurs

Upendra Kaul (U)

Batra Heart Centre and Dean Academics and Research of BHMRC, Batra Hospital & Medical Research Centre, 1, Tughlakabad Institutional Area, Mehrauli Badarpur Road, New Delhi, 110 062, India. kaul.upendra@gmail.com.

Saumitra Ray (S)

Heart Clinic, Kolkata, West Bengal, 700019, India.

D Prabhakar (D)

Apollo First Med Hospitals, Chennai, 600 010, India.

Arun Kochar (A)

Fortis Hospital, Mohali, Punjab, 160062, India.

Kamal Sharma (K)

SAL Hospital & Medical Institute, Ahmedabad, Gujarat, 380054, India.

Prakash Kumar Hazra (PK)

AMRI Hospital, Kolkata, West Bengal, 700029, India.

Subhash Chandra (S)

BLK Super Speciality Hospital, Pusa Road, Karol Bagh, New Delhi, 110005, India.

Dharmesh Ramakant Bhai Solanki (DRB)

Cardiac Consultants, 502/503 Hem Arcade, Dr Yagnik Road, Yagnik Road, Rajkot, 360001, India.

Anjan Lal Dutta (AL)

Peerless Hospital, Pancha Sayar Rd, Sahid Smirity Colony, Pancha Sayar, 700094, Kolkata, West Bengal, India.

Viveka Kumar (V)

Cath Labs MSSH (East) Saket, Max Super Speciality Hospital, New Delhi, 110017, India.

M Srinivas Rao (MS)

Care Hospitals, Road No 1, Banjara Hills, Hyderabad, 500034, India.

Abraham Oomman (A)

Apollo Hospitals Greams Road Chennai, Apollo Hospitals 21, Greams Lane, Off Greams Road, Chennai, 600 006, India.

Sameer Dani (S)

Apollo Hospitals, Plot No.1 A, Bhat GIDC Estate, Gandhinagar, Gujarat, 382428, India.

Brian Pinto (B)

Holy Family Hospital, Mumbai, 400 050, India.

T R Raghu (TR)

Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, 560 069, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Système cardiovasculaire › Consensus document: management of heart...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Pensée (activité mentale) › Prise de décision › Consensus › Consensus document: management of heart...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › Consensus document: management of heart...
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Défaillance cardiaque › Consensus document: management of heart...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Consensus document: management of heart...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › Consensus document: management of heart...